Clene Inc. Expert Perspectives Webinar on Cellular Energetic Failure: Addressing Unmet Needs and a New Investigational Treatment for ALS and MS
4:30 pm - 6:00 pm EST
The webinar will feature presentations by two experts: Professor of Neurology Matthew Kiernan, PhD, DSc, FRACP, FAHMS, AM, MBBS and Professor of Neurology Benjamin Greenberg, MD, MHS, FANA, FAAN, CRND, who will discuss the current treatment landscape and unmet medical needs in amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).
Following the experts’ presentations, Clene’s management team will give an overview of its lead candidate, CNM-Au8, which is a stable, aqueous suspension of catalytically active gold nanocrystals that address cellular energetic failure and oxidative stress by facilitating electron transfer in the brain to increase cellular energy, enhance neurorepair, and improve neuroprotection. Company management will also provide an overview of upcoming milestones, which include the expected release of top line data from the placebo-controlled, Phase 2, RESCUE-ALS trial in the second half of 2021.
Clene’s management team as well as Drs. Kiernan and Greenberg will be available to answer questions following the formal presentations.